Interleukin-2 (IL-2) is a key cytokine that regulates T-cell growth, activation, and differentiation. Mainly produced by activated CD4+ T-helper cells, it&rsquo;s also secreted by CD8+ T-cells and NK cells. IL-2 supports T-cell expansion and survival during immune responses, enhancing both helper and cytotoxic T-cell functions, especially against infections and tumors.
<h3 dir="ltr">Epidemiology Segmentation</h3>
<ul>
<li dir="ltr" aria-level="1">
Total Cases of Selected Indications
</li>
<li dir="ltr" aria-level="1">
Indication-wise Eligible Cases
</li>
<li dir="ltr" aria-level="1">
Indication-wise Treated Cases
</li>
</ul>
<h2 dir="ltr">Interleukin-2 (IL-2) Epidemiology</h2>
<ul>
<li dir="ltr" aria-level="1">
In 2024, the 7MM reported around 22 million eligible cases across all selected IL-2 indications.
</li>
<li dir="ltr" aria-level="1">
Atopic dermatitis accounted for the highest number of IL-2-eligible cases in the 7MM.
</li>
<li dir="ltr" aria-level="1">
In the U.S., non-segmental vitiligo (NSV) had approximately 1.7 million eligible cases in 2024.
</li>
</ul>
<h2 dir="ltr"><a href="https://www.delveinsight.com/report-store/interleukin-2-market-forecast">Interleukin-2 (IL-2) Market</a></h2>
<ul>
<li dir="ltr" aria-level="1">
In 2024, the total IL-2 market size in the 7MM was approximately USD 68 million.
</li>
<li dir="ltr" aria-level="1">
The U.S. dominated the market, contributing about 83%, followed by Japan with 17%.
</li>
<li dir="ltr" aria-level="1">
Among EU4 and the UK, Rezpegaldesleukin (REZPEG/NKTR-358) is expected to hold the largest market share by 2034.
</li>
<li dir="ltr" aria-level="1">
By indication, melanoma led the market in 2024, followed by peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL) in the 7MM.
</li>
</ul>
<h3 dir="ltr">Interleukin-2 (IL-2) Market Drivers</h3>
<ul>
<li dir="ltr" aria-level="1">
IL-2 is being explored across multiple indications, including autoimmune diseases and cancers, boosting its therapeutic potential.
</li>
<li dir="ltr" aria-level="1">
Modified IL-2 molecules with improved safety and efficacy profiles are driving renewed interest and investment in IL-2-based therapies.
</li>
<li dir="ltr" aria-level="1">
A robust pipeline supported by partnerships between biotech and pharma companies is accelerating IL-2 development and commercialization.
</li>
</ul>
<h3 dir="ltr">Interleukin-2 (IL-2) Market Barriers</h3>
<ul>
<li dir="ltr" aria-level="1">
High-dose IL-2 therapies are associated with severe side effects, limiting broader clinical use.
</li>
<li dir="ltr" aria-level="1">
Complex formulation and delivery challenges increase R&amp;D costs, posing hurdles for smaller companies.
</li>
<li dir="ltr" aria-level="1">
IL-2 therapies face stiff competition from other cytokine-based and immune checkpoint therapies, which may impact adoption.
</li>
</ul>
<h3 dir="ltr"><a href="https://www.delveinsight.com/report-store/interleukin-2-il-2-inhibitor-pipeline-insight">Emerging Interleukin-2 (IL-2) Therapies</a></h3>
<ul>
<li dir="ltr" aria-level="1">
Nemvaleukin Alfa
</li>
<li dir="ltr" aria-level="1">
Soquelitinib
</li>
<li dir="ltr" aria-level="1">
Darleukin
</li>
<li dir="ltr" aria-level="1">
Rezpegaldesleukin
</li>
<li dir="ltr" aria-level="1">
ILT-101
</li>
</ul>
And others.
&nbsp;
<h3 dir="ltr">Interleukin-2 (IL-2) Key Players</h3>
<ul>
<li dir="ltr" aria-level="1">
Mural Oncology
</li>
<li dir="ltr" aria-level="1">
Corvus Pharmaceuticals
</li>
<li dir="ltr" aria-level="1">
Philogen
</li>
<li dir="ltr" aria-level="1">
Merck
</li>
<li dir="ltr" aria-level="1">
Nektar
</li>
<li dir="ltr" aria-level="1">
Cue Biopharma
</li>
<li dir="ltr" aria-level="1">
Krystal Biotech
</li>
<li dir="ltr" aria-level="1">
ILTOO Pharma
</li>
<li dir="ltr" aria-level="1">
Innovent
</li>
<li dir="ltr" aria-level="1">
Regeneron Pharmaceuticals
</li>
<li dir="ltr" aria-level="1">
R2T Biopharma (XEME Biopharma)
</li>
<li dir="ltr" aria-level="1">
GI Innovation, AstraZeneca and Merck (MSD)
</li>
<li dir="ltr" aria-level="1">
GI Innovation and Merck
</li>
<li dir="ltr" aria-level="1">
R2T Biopharma (XEME Biopharma)
</li>
<li dir="ltr" aria-level="1">
Sanofi
</li>
<li dir="ltr" aria-level="1">
Synthekine
</li>
<li dir="ltr" aria-level="1">
BioNTech
</li>
<li dir="ltr" aria-level="1">
Medicenna Therapeutics
</li>
<li dir="ltr" aria-level="1">
Ascendis Pharma
</li>
<li dir="ltr" aria-level="1">
Sanofi/Synthorx
</li>
<li dir="ltr" aria-level="1">
Cugene/AbbVie
</li>
<li dir="ltr" aria-level="1">
Deka Biosciences
</li>
<li dir="ltr" aria-level="1">
Dragonfly Therapeutics
</li>
<li dir="ltr" aria-level="1">
Werewolf Therapeutics
</li>
<li dir="ltr" aria-level="1">
Xilio Therapeutics
</li>
<li dir="ltr" aria-level="1">
Bioniz Therapeutics/Equillium
</li>
<li dir="ltr" aria-level="1">
Asher Bio
</li>
<li dir="ltr" aria-level="1">
Synthekine
</li>
<li dir="ltr" aria-level="1">
Anaveon
</li>
<li dir="ltr" aria-level="1">
Aulos Bioscience
</li>
<li dir="ltr" aria-level="1">
Selecxine/ProBio
</li>
<li dir="ltr" aria-level="1">
Hoffmann-La Roche
</li>
<li dir="ltr" aria-level="1">
TILT Biotherapeutics
</li>
</ul>
And others.